These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index. Chansky PB; Olazagasti JM; Feng R; Werth VP J Am Acad Dermatol; 2018 Sep; 79(3):464-469.e2. PubMed ID: 29066273 [TBL] [Abstract][Full Text] [Related]
7. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606 [No Abstract] [Full Text] [Related]
8. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Ang GC; Werth VP Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300 [TBL] [Abstract][Full Text] [Related]
9. The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: A comprehensive review. Ahmed S; Chen KL; Werth VP Semin Arthritis Rheum; 2020 Jun; 50(3):458-462. PubMed ID: 32057402 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. Tiao J; Feng R; Berger EM; Brandsema JF; Coughlin CC; Khan N; Kichula EA; Lerman MA; Lvovich S; McMahon PJ; Rider LG; Rubin AI; Scalzi LV; Smith DM; Taxter AJ; Treat JR; Williams RP; Yum SW; Okawa J; Werth VP Br J Dermatol; 2017 Oct; 177(4):1086-1092. PubMed ID: 28421601 [TBL] [Abstract][Full Text] [Related]
11. The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. Tiao J; Feng R; Bird S; Choi JK; Dunham J; George M; Gonzalez-Rivera TC; Kaufman JL; Khan N; Luo JJ; Micheletti R; Payne AS; Price R; Quinn C; Rubin AI; Sreih AG; Thomas P; Okawa J; Werth VP Br J Dermatol; 2017 Feb; 176(2):423-430. PubMed ID: 28004387 [TBL] [Abstract][Full Text] [Related]
12. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis. Ahmed S; Chakka S; Concha J; Krain R; Feng R; Werth VP Br J Dermatol; 2020 Apr; 182(4):949-954. PubMed ID: 31206600 [TBL] [Abstract][Full Text] [Related]
13. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Anyanwu CO; Fiorentino DF; Chung L; Dzuong C; Wang Y; Okawa J; Carr K; Propert KJ; Werth VP Br J Dermatol; 2015 Oct; 173(4):969-74. PubMed ID: 25994337 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Femia AN; Vleugels RA; Callen JP Am J Clin Dermatol; 2013 Aug; 14(4):291-313. PubMed ID: 23754636 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Klein RQ; Bangert CA; Costner M; Connolly MK; Tanikawa A; Okawa J; Rose M; Fakharzadeh SS; Fiorentino D; Lee LA; Sontheimer RD; Taylor L; Troxel AB; Werth VP Br J Dermatol; 2008 Sep; 159(4):887-94. PubMed ID: 18616782 [TBL] [Abstract][Full Text] [Related]
16. Clinical phenotypes and therapeutic responses in cutaneous-predominant sarcoidosis: 6-year experience in a tertiary referral service. Paolino A; Galloway J; Birring S; Brex P; Larkin G; Patel A; Sado D; Murgatroyd F; Walsh S Clin Exp Dermatol; 2021 Aug; 46(6):1038-1045. PubMed ID: 33608920 [TBL] [Abstract][Full Text] [Related]
17. MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin. Stager K; Wise L BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32998908 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Hornung T; Ko A; Tüting T; Bieber T; Wenzel J Clin Exp Dermatol; 2012 Mar; 37(2):139-42. PubMed ID: 21981743 [TBL] [Abstract][Full Text] [Related]
19. Therapy of polymyositis and dermatomyositis. Marie I; Mouthon L Autoimmun Rev; 2011 Nov; 11(1):6-13. PubMed ID: 21740984 [TBL] [Abstract][Full Text] [Related]
20. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Yassaee M; Fiorentino D; Okawa J; Taylor L; Coley C; Troxel AB; Werth VP Br J Dermatol; 2010 Mar; 162(3):669-73. PubMed ID: 19863510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]